• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SNDL Inc.

    3/27/25 4:08:27 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email
    S-8 1 ss4589060_s8.htm REGISTRATION STATEMENT

     

    Registration No. 333-

     

    As filed with the Securities and Exchange Commission on March 27, 2025

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _____________________________________

     

    FORM S-8

    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933

     _____________________________________ 

     

    SNDL INC.

    (Exact name of registrant as specified in its charter)

    Province of Alberta
    (State or other jurisdiction of incorporation or organization)
      Not Applicable
    (I.R.S. Employer Identification No.)

     

    #300, 919 – 11 Avenue SW

    Calgary, AB, Canada T2R 1P3

    (403) 948-5227

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    SUNDIAL GROWERS INC. RESTRICTED AND PERFORMANCE SHARE UNIT PLAN JULY 29, 2019

    (Full title of the plan)

    _____________________________________

    Corporation Service Company

    19 West 44th Street, Suite 200
    New York, NY 10036

    (Name and address of agent for service)

     

    (800) 927-9800

    (Telephone number, including area code, of agent for service)

    _____________________________________

    With a copy to:

     

      Doreen E. Lilienfeld, Esq.

    Ryan E. Robski, Esq.
    Allen Overy Shearman Sterling US LLP
    599 Lexington Avenue
    New York, NY 10022
    (212) 848-4000

      

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐ Accelerated filer 🗷
    Non-accelerated filer ☐ Smaller reporting company ☐
      Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     
     

    EXPLANATORY NOTE

     

    SNDL Inc. (the “Registrant”) is filing this registration statement on Form S-8 pursuant to and in accordance with General Instruction E of Form S-8 to register 8,000,000 additional common shares, no par value per share (“Common Shares”), for issuance under the Sundial Growers Inc. Restricted and Performance Share Unit Plan July 29, 2019 (the “Plan”). The Registrant first registered the offer and sale of 8,939,255 Common Shares (without giving effect to the Registrant’s 10-for-1 share consolidation that became effective on July 25, 2022 (the “Share Consolidation”) on a pre-Share Consolidation basis, or 893,926 shares of Common Shares on a post-Share Consolidation basis) in connection with the Plan on its registration statement on Form S-8 (File No. 333-233156) filed with the Securities and Exchange Commission (the “Commission”) on August 8, 2019, subsequently amended by post-effective amendment on Form S-8 on September 19, 2022 (the “First Registration Statement”). On January 19, 2022, the Registrant registered 21,118,760 additional Common Shares (on a pre-Share Consolidation basis, 2,111,876 Common Shares on a post-Share Consolidation basis) in connection with the Plan on its registration statement on Form S-8 (File No. 333-262233) filed with the Commission, which was subsequently amended by post-effective amendment on Form S-8 on September 19, 2022 (the “Second Registration Statement”). On September 19, 2022, the Registrant registered 180,000 additional Common Shares in connection with the Plan on its registration statement on Form S-8 (File No. 333-267510) filed with the Commission on September 19, 2022 (the “Third Registration Statement”). On January 17, 2023, the Registrant registered 10,000,000 additional Common Shares in connection with the Plan on its registration statement on Form S-8 (File No. 333-269242) filed with the Commission on January 17, 2023 (the “Fourth Registration Statement”). On April 15, 2024, the Registrant registered 8,000,000 additional Common Shares in connection with the Plan on its registration statement on Form S-8 (File No. 333-278683) filed with the Commission on April 15, 2024 (together with the First Registration Statement, the Second Registration Statement, the Third Registration Statement and the Fourth Registration Statement, the “Prior Registration Statements”).

     

    In accordance with General Instruction E of Form S-8, the contents of the Prior Registration Statements filed on August 8, 2019, January 19, 2022 (each as amended on September 19, 2022, and filed on September 19, 2022), January 17, 2023 and April 15, 2024 are hereby incorporated by reference. Only those items of Form S-8 containing new information not contained in the Prior Registration Statements are presented herein.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.Incorporation of Documents by Reference.

    The following documents filed with the Commission are hereby incorporated by reference:

     

    (a)The Registrant’s Annual Report on Form 40-F for the year ended December 31, 2024, as filed with the Commission on March 18, 2025 (Commission File No. 001-39005).

    (b)The description of securities registered under Section 12 of the Exchange Act included as Exhibit 2.2 of the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2022, as filed with the Commission on April 24, 2023 (Commission File No. 001-39005).

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents, provided, however, that the Registrant is not incorporating by reference any information in these documents or filings that is deemed “furnished” to and not filed with the Commission (except for documents or information deemed to have been specifically incorporated by reference as discussed in (3) above).

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     
     

     

    Item 8. Exhibits.

     

    Exhibit Number   Description
    4.1   The Registrant’s Articles of Incorporation, as currently in effect (incorporated by reference to exhibit 4.1 to the Registrant’s Registration Statement on Form S-8, filed with the Commission on August 8, 2019 (File No. 333-233156))
    4.2   The Registrant’s bylaws, as currently in effect (incorporated by reference to exhibit 3.2 to the Registrant’s registration statement on Form F-1/A, filed with the Commission on July 30, 2019 (File No. 333-232573))
    4.3   Sundial Growers Inc. Restricted and Performance Share Unit Plan July 29, 2019 (incorporated by reference to Exhibit 4.2 to the  Registrant’s registration statement on Form S-8, filed with the Commission on August 8, 2019 (File No. 333-233156))
    5.1*   Opinion of McCarthy Tétrault LLP, with respect to the legality of the securities being registered
    23.1*   Consent of McCarthy Tétrault LLP (included in the opinion filed as Exhibit 5.1)
    23.2*   Consent of Marcum LLP, independent registered public accounting firm
    24.1*   Power of Attorney (contained on the signature page hereto)
    107.1*   Filing Fee Table

     

    * Filed herewith.

     

     

     

     

     

     

     

     
     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Great Abaco, Bahamas, on this 27th day of March, 2025.

    SNDL INC.
       
       
    By:  /s/ Zachary George
    Name: Zachary George
    Title: Chief Executive Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Zachary George, Alberto Paredero Quiros and Matthew Husson as his or her true and lawful attorney-in-fact and agent, upon the action of any such appointee, with full power of substitution and re-substitution, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which each of said attorneys-in-fact and agents may deem necessary or advisable in order to enable SNDL Inc. to comply with the Securities Act of 1933, as amended (the “Securities Act”), and any requirements of the Securities and Exchange Commission (the “Commission”) in respect thereof, in connection with the filing with the Commission of this registration statement on Form S-8 (“Registration Statement”) under the Securities Act, including specifically, but without limitation, power and authority to sign the name of the undersigned to such registration Statement and any amendments to such Registration Statement (including post-effective amendments), to file the same with all exhibits thereto and other documents in connection therewith with the Commission, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the same together with other documents in connection therewith with the appropriate state securities authorities, granting unto each of said attorneys-in-fact and agents full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed this 27th day of March, 2025 by the following persons in the following capacities:

     

    Signature   Title  
           
    /s/ Zachary George  

    Chief Executive Officer and Director

    (Principal Executive Officer)

     
    Zachary George    
           
    /s/ Alberto Paredero Quiros  

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

     
    Alberto Paredero Quiros    
           
    /s/ Greg Mills   Non-Executive Chairman and Director  
    Greg Mills    
           
    /s/ Gregory Turnbull   Director  
    Gregory Turnbull    
           
    /s/ Lori Ell   Director  
    Lori Ell    
           
        Director  
    Bryan Pinney    
           
        Director  
    Frank Krasovec    
           
    /s/ J. Carlo Cannell   Director  
    J. Carlo Cannell    

     

     

     
     

     

    AUTHORIZED UNITED STATES REPRESENTATIVE

    Pursuant to the requirements of the Securities Act, this Registration Statement on Form S-8 has been signed below by the undersigned, solely in its capacity as the Registrant’s duly authorized representative in the United States, on March 27, 2025.

     

    /s/ Donald J. Puglisi

    Donald J. Puglisi

    Managing Director, Puglisi & Associates

     

     

     

     

     


     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $SNDL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNDL

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $SNDL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SNDL Reports First Quarter 2025 Financial and Operational Results

      The Company Delivers Record Gross Margin and Positive Cash Flow; Announces Strategic Review of U.S. Platform and Listing Structure EDMONTON, AB, May 1, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the first quarter ended March 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference cal

      5/1/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL Launches Rise Rewards Loyalty Program

      EDMONTON, AB, April 22, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is excited to announce the launch of its highly anticipated Rise Rewards loyalty program, designed to help Value Buds customers save more, earn more, and get even more from every visit. Starting April 22, 2025, Rise Rewards will be available at all Value Buds locations in Alberta, Ontario, Saskatchewan, and Manitoba. "Our vision is always focused on the consumer experience, and our Rise Rewards program is an exciting tool to provide even more value for the Value Buds shoppe

      4/22/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL to Announce First Quarter 2025 Financial Results on May 1, 2025

      EDMONTON, AB, April 14, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2025 financial results for the period ended March 31, 2025, before market opens on Thursday, May 1, 2025. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on May 1, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/4ikuz377 ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), th

      4/14/25 4:30:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on SNDL Inc.

      Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

      7/17/24 12:19:57 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • Sundial Growers upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

      8/16/22 7:59:34 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • Sundial Growers upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Sundial Growers from Underperform to Market Perform and set a new price target of $0.70 from $0.60 previously

      5/3/22 7:19:03 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    Financials

    Live finance-specific insights

    See more
    • SNDL Reports First Quarter 2025 Financial and Operational Results

      The Company Delivers Record Gross Margin and Positive Cash Flow; Announces Strategic Review of U.S. Platform and Listing Structure EDMONTON, AB, May 1, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the first quarter ended March 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference cal

      5/1/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL to Announce First Quarter 2025 Financial Results on May 1, 2025

      EDMONTON, AB, April 14, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2025 financial results for the period ended March 31, 2025, before market opens on Thursday, May 1, 2025. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on May 1, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/4ikuz377 ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), th

      4/14/25 4:30:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL Reports Fourth Quarter and Full Year 2024 Financial and Operational Results

      The Company reports Record Full Year Net Revenue, Gross Profit and Gross Margin, as well as positive Cash Flow and Free Cash Flow  CALGARY, AB, March 18, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2024. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation and shareholder letter on its website, found at https://sndl.com. The Co

      3/18/25 7:00:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    Leadership Updates

    Live Leadership Updates

    See more
    • SNDL Appoints New Chief Information Officer and New President, Liquor Division

      CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

      11/21/24 6:02:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SNDL Announces 2024 Annual General Meeting Results

      CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

      7/30/24 5:45:00 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • Skymint Assets Acquired from Receivership; Sunstream USA Builds on Parallel Acquisition

      CALGARY, AB, Oct. 13, 2023 /PRNewswire/ - SunStream Bancorp Inc. ("SunStream") is pleased to announce a receivership court order (the "Sale Order") granting the sale of certain assets of Greenpeak Industries Inc. and certain affiliated entities d.b.a. Skymint ("Skymint") to Skymint Acquisition Co. (the "Skymint Transaction"), a newly formed designee entity of Tropics LP ("Tropics"). Tropics is a limited partnership fully owned by an affiliate of Sunstream, a joint venture sponsored by SNDL Inc. (NASDAQ:SNDL) ("SNDL").  Skymint Acquisition Co. is anticipated to be part of the S

      10/13/23 8:37:00 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    SEC Filings

    See more
    • SEC Form 6-K filed by SNDL Inc.

      6-K - SNDL Inc. (0001766600) (Filer)

      5/1/25 7:21:29 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by SNDL Inc.

      6-K - SNDL Inc. (0001766600) (Filer)

      4/30/25 7:55:52 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by SNDL Inc.

      6-K - SNDL Inc. (0001766600) (Filer)

      4/22/25 7:32:45 AM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care

    $SNDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

      SC 13G/A - SNDL Inc. (0001766600) (Filed by)

      1/31/24 4:48:48 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

      SC 13G/A - SNDL Inc. (0001766600) (Subject)

      2/14/23 5:28:02 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

      SC 13G/A - SNDL Inc. (0001766600) (Filed by)

      2/13/23 4:06:09 PM ET
      $SNDL
      Medicinal Chemicals and Botanical Products
      Health Care